South San Francisco-based Hyperion Therapeutics has pocketed $40 million from its second round of venture capital. Sofinnova Ventures led the round with equal commitments by Highland Capital Partners and NEA, all of Menlo Park, CA. WRF Capital of Seattle, WA also participated
"The funding will allow us to complete the licensing deal with Medicis Pharmaceutical Corporation, build out our management team, advance our clinical trials in Urea Cycle Disorders and Hepatic Encephalopathy and begin the U.S. promotion of the only two FDA-approved compounds for the treatment of UCD," says Hyperion CEO Chris Rivera.
- check out the release for more information